12 results about "Animal Disease Models" patented technology

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

The present invention relates to the technical field of biomedicine and discloses use of a hypoxanthine derivative in the preparation of a drug for treating cardiomyopathy and / or myocardial fibrosis. By assaying pharmacological activities of structurally modified and altered hypoxanthine derivatives in treating cardiomyopathy and / or myocardial fibrosis, the pharmacological activities of such compounds were tested in various animal disease models, and data on activities for preventing and treating different types of cardiomyopathy and / or myocardial fibrosis were provided. It is proven that the hypoxanthine derivatives all have good activities, the effects are significantly superior to those of a clinically commonly used drug, nintedanib, and the effects are also significantly superior to those of hypoxanthine derivatives A, B, and C and other hypoxanthine derivatives in the prior art. The hypoxanthine derivative of the present invention can provide a novel skeleton for the screening of new compounds for the preparation of a drug for treating cardiomyopathy and / or myocardial fibrosis.

The present invention relates to the technical field of biomedicine and discloses use of a hypoxanthine derivative in the preparation of a drug for treating renal fibrosis and / or kidney disease. By assaying pharmacological activities of structurally modified and altered hypoxanthine derivatives for treating renal fibrosis and / or kidney disease, the pharmacological activities of such compounds were tested in animal disease models, and data on activities for preventing and treating renal fibrosis and / or kidney disease were provided. It is proven that the hypoxanthine derivatives have good activities, and the effects are significantly superior to those of clinically commonly used positive drugs nintedanib and losartan, and the effects are also significantly superior to those of hypoxanthine derivatives A, B, and C and other hypoxanthine derivatives in the prior art. The hypoxanthine derivative of the present invention can provide a novel skeleton for the screening of novel compounds for the preparation of a drug for treating renal fibrosis and / or kidney disease.

The present invention relates to the technical field of biomedicine. Disclosed is use of a hypoxanthine derivative in the preparation of a drug for treating peritoneal diseases. By detecting the pharmacological activity of structurally modified and engineered hypoxanthine derivatives in treating peritoneal diseases, the pharmacological activity of such compounds is tested in various animal disease models, and data on their activity in preventing and treating different types of peritoneal diseases are provided, confirming that the hypoxanthine derivatives all exhibit good activity. The effect is significantly better than that of a commonly used clinical drug, nintedanib, and the effect is also significantly better than that of hypoxanthine derivatives A, B, and C, and other hypoxanthine derivatives in the prior art. The hypoxanthine derivatives provided in the present invention can offer a novel scaffold for the screening of new compounds for the preparation of drugs for treating peritoneal diseases, laying a theoretical foundation for the development of novel lead compounds.

The invention relates to the technical field of biological medicines, and discloses an application of an inoxanthine derivative in preparation of a medicine for treating peritoneal diseases, the pharmacological activity of the compound is tested in various animal disease models by detecting the pharmacological activity of the inoxanthine derivative subjected to structure modification and transformation in treatment of peritoneal diseases, and the application of the inoxanthine derivative in preparation of the medicine for treating peritoneal diseases is provided. The invention also provides data of activity of preventing and treating different types of peritoneal diseases, which proves that the compound has good activity, the effect is obviously superior to that of a clinically common drug nintedanib, and the effect is also obviously superior to that of hypoxanthine derivatives A, B and C and other hypoxanthine derivatives in the prior art. The hypoxanthine derivative provided by the invention can provide a novel skeleton for screening a novel compound for preparing a medicine for treating peritoneal diseases, and lays a theoretical foundation for developing a novel lead compound.

The invention relates to the field of animal disease models, and discloses an improved progressive immune checkpoint inhibitor related myocarditis mouse model as well as a construction method and application thereof. The construction method of the model comprises the steps that 0.1 mL of a Freund's complete adjuvant mixed solution is subcutaneously injected into a mouse on the 0th day and the 7th day, and the solution contains 0.25 mg of a mouse cardiac troponin I immunogenic peptide fragment; the method is characterized in that a PD-1 inhibitor and a CTLA-4 inhibitor are jointly injected into a mouse in a caudal vein mode at the frequency of one time every two days from the eighth day, the injection dosage of each drug is 5 mg / kg per time, and the injection process is carried out for 5 times in total. According to the application, cardiac inflammation caused by ICIs drugs is induced through combined use of various reagents, and a disease outcome stage of a patient in the real world is perfectly simulated through dose control and injection method improvement, so that a bedding effect is achieved for clinical research and drug test.

The invention relates to the technical field of biological medicines, and discloses an application of an inosine derivative in preparation of medicines for treating non-alcoholic fatty liver diseases and hepatic fibrosis, and the pharmacological activity of the inosine derivative subjected to structural modification and transformation in treatment of the non-alcoholic fatty liver diseases and / or hepatic fibrosis is detected. The pharmacological activity of the compound is tested in various animal disease models, and data for preventing and treating different types of non-alcoholic fatty liver diseases and / or hepatic fibrosis activity is provided, so that the compound is proved to have good activity, and the effect is obviously superior to that of a clinically common positive drug nintedanib; the effect is obviously superior to those of hypoxanthine derivatives A, B and C and other hypoxanthine derivatives in the prior art. The hypoxanthine derivative disclosed by the invention can provide a novel skeleton for screening a novel compound for preparing a medicine for treating the non-alcoholic fatty liver disease and / or hepatic fibrosis, and lays a theoretical foundation for developing a novel lead compound.

The application relates to the technical field of animal disease models, and discloses a pathological myopia animal model establishment method and application without eye intervention, which comprises the following steps: using a Hemin solution to intervene in an animal to obtain a pathological myopia animal model. The method can establish a pathological myopia animal model.

The invention relates to a construction method and application of a plateau pulmonary hypertension rat model, and belongs to the technical field of animal disease model construction. The method comprises the following steps: firstly, selecting healthy male SD (Sprague Dawley) rats which are 5-6 weeks old and have the weight of 220 + / -10g, and adaptively feeding the rats in a standard SPF (Specific Pathogen Free) animal room for 7 days; dividing the rats into a healthy control group and a plateau hypoxia group; feeding the rats of the healthy control group in a normal-oxygen normal-temperature standard environment for 28 days; placing the rats of the plateau hypoxia group in the multifunctional plateau environment experiment system for intermittent exposure for 28 days; the intermittent exposure method specifically comprises the following steps: placing the rats in a simulated plateau low-oxygen-low-temperature-low-pressure composite stress environment in 12 hours of a daily illumination period; if the dark period is 12 hours, the rat is moved out to a normal-oxygen normal-temperature standard environment to be recovered. The rat model shows typical pulmonary arterial hypertension characteristics, all indexes are stable and repeatable, and a reliable basis is provided for research.

The invention relates to a construction method of a tophus mouse model, relates to the technical field of animal disease model construction, and is used for solving one of the problems of long modeling period, limited maintenance time, tedious operation, harsh conditions and the like of a tophus animal model in the prior art. The construction method of the tophus mouse model comprises the following steps: step 1, preparing a urate crystal-matrigel suspension; and 2, injecting the urate crystal-matrigel suspension prepared in the step 1 into the subcutaneous tissue of the back of a mouse. According to the construction method of the gouty stone mouse model, the experiment threshold and operation cost are low, repeatability is good, stability is high, the core pathological process of the gouty stone can be stably represented, the nodule and crystal morphology, the deposition state and the inflammatory characteristics can stably exist for at least four weeks after modeling, and the model has good application prospects. The requirements of long-term lesion observation, pathogenesis research and long-acting drug screening of the tophus are met.

The invention relates to the technical field of biological medicines, and discloses an application of a hypoxanthine derivative in preparation of a medicine for treating renal fibrosis and / or nephropathy, and the pharmacological activity of the hypoxanthine derivative subjected to structure modification and transformation is detected to treat renal fibrosis and / or nephropathy. The pharmacological activity of the compound is tested in an animal disease model, and the data of the activity of preventing and treating renal fibrosis and / or nephropathy is provided, which proves that the compound has good activity, and the effect is obviously superior to that of clinically common positive drugs nintedanib and losartan; the effect is obviously superior to those of hypoxanthine derivatives A, B and C and other hypoxanthine derivatives in the prior art. The hypoxanthine derivative disclosed by the invention can provide a novel skeleton for screening a novel compound for preparing a medicine for treating renal fibrosis and / or nephropathy, and lays a theoretical foundation for developing a novel lead compound.

The application of a hypoxanthine derivative in the preparation of drugs for treating pulmonary fibrosis was investigated. The pharmacological activity of the modified hypoxanthine derivative in treating pulmonary fibrosis was tested in various animal disease models. Data on the activity of this compound in preventing and treating different types of pulmonary fibrosis were provided, confirming that it has good activity and is significantly better than the clinically commonly used positive control drug nintedanib. It is also significantly better than hypoxanthine analogs A, B, C, and D and other hypoxanthine analogs in the prior art.